Ribbon Biolabs, a DNA synthesis firm, announced today the successful launch of their unique InfiniSynthTM technology for the automated assembly of sequence-agnostic and lengthy DNA. Ribbon Biolabs reached this milestone in conjunction with HighRes® Biosolutions, a renowned provider of laboratory automation technologies. Ribbon Biolabs will be able to join the market in 2023 with a highly distinctive approach to offering crucial tools for life science research and biopharmaceutical development thanks to the InfiniSynthTM platform.
Ribbon Biolabs has created a revolutionary approach for the high-throughput, automated synthesis of complex DNA. Ribbon Biolabs intends to become the leading partner for DNA-based solutions and thereby actualize the disruptive potential of synthetic biology by addressing the rising market for synthetic DNA of multi-kbp to sub-genomic size, a crucial component for biopharmaceutical research and development.
“The successful setup of our first automated production line for synthetic long DNA is another milestone allowing us to bring DNA-based solutions to the biotechnology industry on a commercial scale,” said Marc J. Brehme, Ph.D. Chief Technology Officer of Ribbon Biolabs. “We value the collaboration with HighRes® Biosolutions that supported the achievement of this milestone which positions us to enable the next wave of innovation in biotech.”
The InfiniSynthTM technology combines algorithmic sequence processing with combinatorial synthesis optimization and employs robotic automation for exponential enzymatic DNA assembly. This enables the quick and consistent synthesis of DNA molecules with lengths of more than 10,000 base pairs (bp). Ribbon Biolabs is now able to provide commercial-scale synthetic DNA, regardless of length or complexity, to its partners in a timely manner thanks to the automated InfiniSynthTM platform.
“Synthetic biology is ripe for innovation to expand its potential as an enabler for future life-science discoveries and successful research in the biopharmaceutical industry. Ribbon Biolabs has developed an approach to synthesizing long and complex synthetic DNA and we welcomed the chance to collaborate with them,” said Brian J. O’Sullivan, Senior Vice President of Commercial at HighRes® Biosolutions. “With our strength and depth of knowledge in laboratory design and automation, we could contribute to the realization of Ribbon’s technological advances and vision.”
The recent Site Acceptance of the automated manufacturing line also marks a significant achievement within Ribbon Biolabs’ Series A investment, which is scheduled to conclude in early 2022.
Source – Business Wire
